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Available online 5 January 2016The KCL029 human embryonic stem cell line was derived from an embryo donated for research that carried a
c.814 T N C mutation in the WAS gene, which is linked to the Wiskott-Aldrich syndrome, a rare, inherited, X-
linked, recessive disease characterized by immune dysregulation and microthrombocytopenia. The line is also
carrier for a mutation p.N1152H in the gene encoding the cystic ﬁbrosis transmembrane conductance regulator
CFTR. The ICMwas isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both
the derivation and cell line propagation were performed in an animal product-free environment. Pluripotent
state and differentiation potential were conﬁrmed by in vitro assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Ethics The hESC line KCL029 is derived under license from the UK
Human Fertilisation and Embryology Authority (research
license numbers: R0075 and R0133) and also has local
ethical approval (UK National Health Service Research Ethics
Committee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the
experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report. No
ﬁnancial inducements are offered for donation.
. This is an open access article under2. Resource detailsConsent signed Aug 12, 2009
Embryo thawed Aug 23, 2009
UK Stem Cell Bank
Deposit Approval
Dec 01, 2011
Reference: SCSC11-46
Sex Male 46, XY
Grade Research
Disease status
(Fig. 1)
c.814 T N C mutation in the WAS gene and carrier for a
mutation p.N1152H in the gene CFTR
Karyotype (aCGH)
Duplication of approximately 0.23 Mb from the long
arm of chromosome 3;
3q29(197,574,292–197,803,820)×3
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the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Genotyping.Microsatellitemarkers speciﬁc for chromosomes 13, 18, 21, X and Ywere am-
pliﬁed. The allele sizes in bp for markers on chromosomes 13, 18, and 21 are listed in the
table.
Chr Marker Allele 1 Allele 2
13 D13S252 294 298
D13S305 447 455
D13S325 284 293
D13S628 457 457
D13S634 405 415
18 D18S386 352 375
D18S390 360 372
D18S391 217 225
D18S535 482 482
D18S819 400 408
D18S976 476 480
D18S978 207 211
21 D21S11 248 248
D21S1409 212 212
D21S1411 303 308
D21S1435 184 188
D21S1437 311 315
DNA ﬁngerprint
(Table 1)
Allele sizes (in bp) of 17 microsatellite markers
speciﬁc for chromosomes 13, 18 and 21
Viability testing Pass
Pluripotent markers
(immunostaining)
(Fig. 2)
NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
Three germ layers
differentiation in vitro
(immunostaining)
(Fig. 3)
Endoderm: AFP (α-fetoprotein)
Ectoderm: TUBB3 (tubulin, β3 class III)
Mesoderm: ACTA2 (actin, α2, smooth muscle)
Sibling lines available No
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190 C. Miere et al. / Stem Cell Research 16 (2016) 189–191We generated KCL029 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012). The
expression of the pluripotency markers was tested after freeze/thaw
cycle (Fig. 2). Differentiation potential into three germ layers was
veriﬁed in vitro (Fig. 3).3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in the meantime new versions of PIS/consent are im-
plemented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (PGD-V.8) were created on Jul. 01, 2010.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 8 – R.2 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on Jan. 20, 2011. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 8 – R.2. HFEA
Code of Practice Edition 8 – R.2 was in effect Apr. 07, 2010–Apr. 06,
2011.3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).Fig. 1. Genetic pedigree tree. Both parents were carryingmutation in CFTR gene. Maternal CFTR
carried c.814 T N Cmutation inWAS gene. The embryos were ﬁrst genotyped formutation in CF
WAS gene. Ab, abnormal; Af, affected; C, carrier; NA, non-applicable; ND, not determined.3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed
mechanically from outgrowth (Ilic et al., 2007; Ilic et al., 2010). hESC
colonies were expanded and cryopreserved at the third passage.
3.4. Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
3.5. Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
3.6. Differentiation
Spontaneous differentiation into three germ layers was assessed in
vitro and in vivo as described (Petrova et al., 2014; Ilic et al., 2012;
Stephenson et al., 2012).mutation was p.N1152H and paternal ΔF508 and exon 2 deletion. In addition, themother
TR gene and then only normal and career embryos were assessed further for a mutation in
Fig. 2. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
ﬁbers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 100 μm.
Fig. 3.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 100 μm.
191C. Miere et al. / Stem Cell Research 16 (2016) 189–1913.7. Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as
described (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.8. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
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